This page shows the latest Q1 sales news and features for those working in and with pharma, biotech and healthcare.
In Q2, revenue increased by 17% to $7.3bn when excluding COVID-19 vaccine sales. ... Sales of its COVID-19 vaccine – sold under the Vaxzevria brand name in Europe – reached $894m in Q2, up from Q1 sales of $275m.
In Q1, Regeneron recorded US net sales of $262m for REGEN-COV under its first contract with the US government.
In March, BioNTech forecast significant sales of 9.8bn for its Pfizer-partnered COVID-19 vaccine in 2021. ... The pharma giant revealed that the vaccine brought in global revenues of $3.5bn during Q1, forecasting that it now expects sales of the jab to
Overall, Pfizer’s Q1 revenues totalled $14.6bn, a 45% increase on the same period last year, reflecting an operational growth of $2.2bn or 42%. ... Although most of this growth was driven by BNT162b2, Pfizer also reported an increase in Q1 2021 sales
Total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020. ... Overall, HIV product sales decreased by 12% to $3.7bn for the first quarter, although sales of its newer HIV treatment Biktarvy increased by 8% year-on-year in Q1.
AstraZeneca has reported ‘solid’ first quarter results, as sales of its COVID-19 vaccine take off and the company’s oncology drugs deliver strong growth. ... Out of those sales, new medicines represented 53% of total revenue globally, compared to 47
More from news
Approximately 1 fully matching, plus 51 partially matching documents found.
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...